<DOC>
	<DOC>NCT02137993</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective disorder.</brief_summary>
	<brief_title>Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>20 years to 65 years Schizophrenia patient with an acute exacerbation Understand the requirement of the study and voluntarily consent to participate in the study Patients who have another psychiatric disorders Patients who have unstable medical conditions Patients who have clinically important abnormalities of liver function test (ï¼ž2.5 fold of upper normal limit), ECG and vital sign at screening visit Uncontrolled diabetic patients (plasma glucose level is more than 126 mg/dl in fasting condition) Patients who have a history of an allergic reaction to olanzapine Patient who have no clinical response to take two or more different atypical antipsychotics for more than 4 weeks. Patient who take clozapine within 12 weeks before screening visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>